CONCLUSIONS: Definitive RP following SOC systemic therapy is safe and appears to be largely feasible robotically. Post-RP urinary QOL was comparable to RP for localized disease (with extrapolated benefit of avoiding symptomatic local disease progression). 25% pT0 response was seen; gene expression profiles of these patients should be sought. Despite a small sample, our analysis lends insight and support to the feasibility of the SWOG 1802 RP arm.
INTRODUCTION AND OBJECTIVES: Radiofrequency (RF) is a type of current that when used with a temperature above 41 C promotes an increase in the production of collagen. Objectives: To describe safety and evaluate the clinical effect of RF in postprostatectomy urinary incontinence (IUPPR) METHODS: This is a pilot study. We included men up to 65 years old, with clinical complaints of IUPPR, who had an ultrasonographic (US) proven post void residual volume (PVRV) < 50 ml, Pad Test of 1 hour > 1 gram and PSA <0.2 ng/ml. Patients with less than 45 days of surgery, urgency urinary incontinence (UUI), patients with neurological degenerative chronic diseases, implantable cardioverter defibrillator and iatrogenic metals in the pelvic region were excluded. The data collection was initiated through a basic anamnestic questionnaire with sociodemographic and clinical information. To assess the clinical response, a 1-hour Pad Test and self-administered questionnaires were performed before and after treatment: ICIQ-SF and ICIQ-OAB At the end of the study, the Likert scale was used to measure the degree of satisfaction with treatment and the modified EVA for urinary incontinence (UI) to assess the course of symptoms. Safety was verified by reporting or observing adverse effects and PVPR verification by US. Participants underwent five sessions of non-ablative endoanal RF. The temperature used in the treatment was 41 C and once achieved, it was kept for 2 minutes, while the therapist performed half-moon movements slowly RESULTS: The sample consisted of 10 men with a mean age of 57.5 AE 4.9 years. The initial Pad Test was 6.5g (1.7-50.0) and the final was 2.0g (0.0-9.0) (p <0.01). The US had no change in PVPR. In the Pad Test, 90% presented decrease and 30% complete resolution of the urinary loss. ICIQ-OAB indicated a significant decrease in irritative micturition symptoms. The ICIQ-SF showed no significant difference. Regarding the degree of satisfaction, two patients were unchanged, six satisfied and two very satisfied. In the report of the patients, four had pain during the positioning of the endoanal electrode, ceasing during the application of RF CONCLUSIONS: RF has been shown to be a safe technique for the treatment of IUPPR, with positive results both in improving urinary loss and in reducing irritative micturition symptoms, promoting patient satisfaction. However, to increase the validity of the study, larger clinical trials are warranted Lack of symptoms as well as the deficiency of highly specific biomarkers has resulted in only 65% of renal cell carcinoma (RCC) cases being diagnosed in stage I. Early detection combined with conventional therapies has resulted in 5-year survival rates of 92.5%; while, 5-year overall survival is less than 11.7% for patients with advanced stage RCC. An effective and non-invasive screening strategy for early diagnosis would be particularly advantageous for RCC patients. Investigation into characteristic metabolomic patterns for disease has the potential to detect changes in cells, tissues, and biofluids that can aid in diagnosis at an early stage.
METHODS: Urine samples were collected from 102 RCC patients and 178 control patients. Samples were collected either in the clinic or in preparation for surgery. An unsupervised model via principle component analysis (PCA) suggested a significant bias within the dataset due to the sample collection; therefore, a subset of age matched patients (n¼66) whose urine was collected in the clinic was selected for a pilot study. The cohort consisted of 32 RCC patients (18 males and 14 females) and 34 control patients (20 male and 14 females) with average ages of 59.3 (range 30-77) and 58.7 (range 41-77), respectively. The urine samples were diluted 1:5 with MeOH and analyzed by positive and negative ion mode HILIC-UPLC-MS in a Q Exactive HF mass spectrometer. A pooled sample was used as a quality control (QC) and during processing to normalize the peak areas. A sample blank was prepared to analyze background signals. For each ionization mode, spectral features (retention time (Rt), m/z pairs) were extracted from the data using Compound Discoverer 2.1. Extracted features were retained that had signal more than 5 times the signal in the sample blank but also were normalized, which occurred when the feature was present in 50% of the QC spectra and had a RSD < 30. The features were then filtered based on two criteria: 1) an adjusted p value less than 0.05 as calculated using a standard student t test, 2) at least a two median fold change. The positive mode and e1196 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Monday, May 21, 2018 negative mode datasets were combined to yield 569 features for the 66 samples. Using the PLS toolbox 8.1.1 (Eigenvector Research Inc.) within MATLAB R2012b, a PCA model built using those 66 samples demonstrated class separation between RCC and control when viewing the score plot of the first two principle components. The features in the dataset were auto-scaled prior to building the model. The dataset was also used to build a supervised orthogonalized partial least squares discriminant analysis (oPLS-DA) model to classify samples with internal cross validation. The features in the dataset were auto-scaled prior to building the model. Cross validation was performed ten times with random subset approach that utilized 1/6 of the dataset to evaluate the model training based on remaining 5/6 of the dataset. RESULTS: Class discrimination was observed in the score plot of the first and second latent variables with cross validated accuracy, sensitivity and specificity were 96.3, 93.9 and 98.8, respectively in differentiating cases from controls. This model demonstrates that the metabolomic urine profile has the potential to be a powerful diagnostic tool.
CONCLUSIONS: A single urine sample subjected to metabolomic profiling can discriminate patients with RCC from controls with exceptionally high accuracy (96.3), sensitivity (93.9) and specificity (98.8). There is potential for clinical translation to screening, detection, the non-invasive diagnosis of small or indeterminate renal masses and the identification of recurrence following treatment. METHODS: In present study, we explored urine metabolome in a cohort of 36 patients with renal tumor (24 RCC and 12 benign renal tumor), and 44 health control using liquid chromatography coupled with high resolution mass spectrometry (LC-MS).
RESULTS: Metabolic profiling of urine could significantly differentiate RCC from the health control and the benign control. Metabolic pathways, including lysine metabolism and phenylalanine metabolism were found to be disturbed in RCC group. Steroid hormone biosynthesis was significant differential between benign and RCC. RCC biomarker was further explored. A metabolite panel consisting of cortolone, testosterone and L-2-aminoadipate adenylate were discovered to have good prediction for RCC from benign with AUC of 0.868 for 10 fold cross-validation. And the panel of aminoadipic acid, 2-(Formamido)-N1-(5-phospho-D-ribosyl)acetamidine and alpha-NPhenylacetyl-L-glutamine could distinct RCC from the health control with AUC of 0.841 10 fold cross-validation.
CONCLUSIONS: This pilot study suggests that urine metabolomics may be useful in differentiating RCC from the control and the benign renal tumor.
